NextCure Inc. has raised $67 million in Series A financing for a plan to commercialize the work of a scientist credited with discovering a key pathway for how cancer drugs harness the immune system. Major investors in the financing include Canaan Partners, Lilly Asia Ventures, OrbiMed Advisors, Pfizer Inc. and Sofinnova Ventures, as well as Alexandria Venture Investments. David Kabakoff, who is the executive partner of Sofinnova Ventures and was a co-founder and chairman of Amplimmune, will serve as NextCure's chairman.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.5 USD | -5.66% |
|
-10.71% | +31.58% |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+31.58% | 44.48M | |
+15.82% | 121B | |
+20.35% | 113B | |
+17.47% | 26.02B | |
-25.31% | 19.39B | |
-19.51% | 15.91B | |
-19.67% | 15.09B | |
-46.87% | 15.06B | |
+62.55% | 14.93B | |
+6.34% | 13.85B |
- Stock Market
- Equities
- NXTC Stock
- News NextCure, Inc.
- David Kabakoff to Join NextCure as Chairman